BCM
KZR

Bayesian Capital Management’s Kezar Life Sciences KZR Stock Holding History

Bayesian Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,722
Closed -$53.9K – 943
2023
Q1 		$53.9K Sell
1,722
-170
-9% -$9.84K 0.01% 713
2022
Q4 		$133K Sell
1,892
-990
-34% -$73.4K 0.02% 646
2022
Q3 		$248K Buy
+2,882
New +$280K 0.05% 467

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bayesian Capital Management's KZR Position: Q2 2023 in Review

Bayesian Capital Management sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 1,722 shares — an estimated $53.9K sold.

Bayesian Capital Management first reported a position in KZR in Q3 2022 and held it in 3 quarters. The position peaked at $248K in Q3 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Bayesian Capital Management reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 1,722 Kezar Life Sciences shares in Q2 2023, an estimated $53.9K.
  • Bayesian Capital Management first reported a position in Kezar Life Sciences in Q3 2022 and held it in 3 quarters.
  • Bayesian Capital Management's Kezar Life Sciences position peaked at $248K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Bayesian Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.